Vasculitis and Giant Cell Arteritis News

Pregnant patients with Takayasu arteritis demonstrate an increased risk for adverse pregnancy outcomes, including hypertension and miscarriage, compared with the general population, according to a meta-analysis published in Nature.

A reduced dosage and updated regimen are now available for the oral small molecule pexidartinib in the treatment of adults with symptomatic tenosynovial giant cell tumor, according to a press release from the drug manufacturer.

Patients with giant cell arteritis may require unexpected and sudden care, with as many as one-third requiring readmission to a health care center within 6 months of an episode, according to data published in Arthritis Care & Research.

In patients with granulomatosis with polyangiitis, those who start induction therapy with rituximab are more likely to achieve remission compared with those who begin cyclophosphamide, according to data published in JAMA Network Open.

Patients who have received a COVID-19 vaccine demonstrate a “slight but significant” change of developing IgA vasculitis, but no more than with other vaccines, according to data published in the Journal of Rheumatology.

The number of patients diagnosed with Kawasaki disease in Japan fell by approximately one-third in 2020, with no indication that parents eschewed necessary hospital visits, according to data published in JAMA Pediatrics.

An artificial intelligence tool called KIDMATCH may be able to accurately distinguish between MIS-C, Kawasaki disease and other similar febrile diseases, according to data published in the Lancet Digital Health.

PHILADELPHIA — An initial double dose of pneumococcal vaccine improves immune response against pneumococcal pneumonia in patients with ANCA-associated vasculitis treated with rituximab, according to data presented at ACR Convergence 2022.

PHILADELPHIA — New classification criteria for pediatric chronic nonbacterial osteomyelitis include chronic bone pain or functional musculoskeletal limitation lasting 6 weeks or longer, according to a speaker at ACR Convergence 2022.

PHILADELPHIA — Patients who are diagnosed with ANCA-associated vasculitis at an older age are more likely to accrue higher levels of systemic damage than patients diagnosed at a younger age, according to data presented at ACR Convergence 2022.